Zhongping (John) Lin
Research Subjects
Zhongping (John) Lin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Naidong Weng
Johnson & Johnson Pharmaceutical Research & Development LLC 1000 Route 202 South Raritan NJ 08869 USA
3 shared publicationsFutian Han
Frontage Laboratories, Inc. 105 Great Valley Parkway Malvern PA 19355 USA
2 shared publicationsHarry Zhao
Frontage Laboratories, Inc. 105 Great Valley Parkway Malvern PA 19355 USA
2 shared publicationsWei Zhang
Frontage Laboratories, Inc., 105 Great Valley Parkway, Malvern, PA 19355, USA
2 shared publicationsKirk Bertelsen
Johnson & Johnson Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
1 shared publicationMike-Qingtao Huang
Johnson & Johnson Pharmaceutical Research & Development, LLC, 1000 Route 202 South, Raritan, NJ 08869, USA
1 shared publication
Latest Publications
- 27 December 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (10) , 1163-1169
Determination of metformin in rat plasma by HILIC‐MS/MS combined with Tecan automation and direct injection
Metformin is a well‐known oral antihyperglycemic drug used in treatment of type II diabetes. Analysis of metformin in biological fluids is a challenge owing to its high polarity and small molecular size, which lead to poor retention of metformin on reversed‐phase liquid chromatographic columns. A high‐throughput method was developed and validated for the determination of metformin in rat plasma in support of preclinical toxicology studies, using hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC‐MS/MS) and Tecan automated sample preparation. Extracted samples were directly injected onto the unbounded silica column with an aqueous–organic mobile phase. This HILIC‐MS/MS method was validated for accuracy, precision, sensitivity, stability, matrix effect, recovery and calibration range. Acceptable intra‐run and inter‐run assay precision (coefficient of variation ≤ 3.9%) and accuracy (99.0–101.8%) were achieved over a linear range of 50–50,000 ng/mL. Metformin is stable in rat plasma for at least 6 h at room temperature, 147 days at −70°C and through three freeze (−70°C) and thaw cycles. Metformin is also stable in rat whole blood for at least 2 h at room temperature and in an ice–water bath. The validated method was successfully used in support of several preclinical studies where metformin is dosed together with an investigational drug substance. The ruggedness of the validated method was demonstrated by the incurred sample reproducibility test. Copyright © 2011 John Wiley & Sons, Ltd.
- 27 December 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (10) , 1163-1169
Determination of metformin in rat plasma by HILIC‐MS/MS combined with Tecan automation and direct injection
Metformin is a well‐known oral antihyperglycemic drug used in treatment of type II diabetes. Analysis of metformin in biological fluids is a challenge owing to its high polarity and small molecular size, which lead to poor retention of metformin on reversed‐phase liquid chromatographic columns. A high‐throughput method was developed and validated for the determination of metformin in rat plasma in support of preclinical toxicology studies, using hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC‐MS/MS) and Tecan automated sample preparation. Extracted samples were directly injected onto the unbounded silica column with an aqueous–organic mobile phase. This HILIC‐MS/MS method was validated for accuracy, precision, sensitivity, stability, matrix effect, recovery and calibration range. Acceptable intra‐run and inter‐run assay precision (coefficient of variation ≤ 3.9%) and accuracy (99.0–101.8%) were achieved over a linear range of 50–50,000 ng/mL. Metformin is stable in rat plasma for at least 6 h at room temperature, 147 days at −70°C and through three freeze (−70°C) and thaw cycles. Metformin is also stable in rat whole blood for at least 2 h at room temperature and in an ice–water bath. The validated method was successfully used in support of several preclinical studies where metformin is dosed together with an investigational drug substance. The ruggedness of the validated method was demonstrated by the incurred sample reproducibility test. Copyright © 2011 John Wiley & Sons, Ltd.
- 23 December 2010
- Published by Taylor & Francis in Bioanalysis
- Vol. 3 (1) , 57-66
Capsule Review on Bioanalytical Method Transfer: Opportunities and Challenges for Chromatographic Methods
With the globalization of drug development activities, transferring a validated bioanalytical procedure to a different site within a pharmaceutical company, or to one or multiple contract research organizations has been dramatically increased in recent years. Undeniably, bioanalytical method transfer is the needed step prior to routine sample analysis at the receiving laboratory. It is clearly stated in the 2001 US FDA Guidance on Bioanalytical Method Validation that a partial validation is needed for method transfer between laboratories. In the current EMA draft guidelines on method validation, the necessity of a method transfer is also emphasized. However, the above guidelines do not give many details on how and when a method transfer validation should be conducted. There is a need for a step-by-step deliberation on the overall strategies, procedures and even technical details for a successful bioanalytical method transfer. In this article, we review the contemporary information available in the scientific literature on method transfer and illustrate various bioanalytical method transfer scenarios using case studies. A 'flexible and fit-for-purpose' bioanalytical method transfer strategy is proposed.
- 23 December 2010
- Published by Taylor & Francis in Bioanalysis
- Vol. 3 (1) , 57-66
Capsule Review on Bioanalytical Method Transfer: Opportunities and Challenges for Chromatographic Methods
With the globalization of drug development activities, transferring a validated bioanalytical procedure to a different site within a pharmaceutical company, or to one or multiple contract research organizations has been dramatically increased in recent years. Undeniably, bioanalytical method transfer is the needed step prior to routine sample analysis at the receiving laboratory. It is clearly stated in the 2001 US FDA Guidance on Bioanalytical Method Validation that a partial validation is needed for method transfer between laboratories. In the current EMA draft guidelines on method validation, the necessity of a method transfer is also emphasized. However, the above guidelines do not give many details on how and when a method transfer validation should be conducted. There is a need for a step-by-step deliberation on the overall strategies, procedures and even technical details for a successful bioanalytical method transfer. In this article, we review the contemporary information available in the scientific literature on method transfer and illustrate various bioanalytical method transfer scenarios using case studies. A 'flexible and fit-for-purpose' bioanalytical method transfer strategy is proposed.
- 1 May 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (15-16) , 1169-1177
Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC–MS/MS—A high throughput approach to evaluate drug–drug interactions
- 1 May 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (15-16) , 1169-1177
Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC–MS/MS—A high throughput approach to evaluate drug–drug interactions